PACE/State of FL - Register now – Sept. 10, 2025

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

Conflict is a natural part of human interaction, and the workplace is not immune from that experience.  Through this microlearning, we'll explore how proper conflict[...]

In recent articles, Mayo Clinic Laboratories emphasizes the transformative potential of recognizing and leveraging the capabilities of a hospital laboratory. With more touchpoints than any other outpatient service line, the laboratory is full of opportunity to enhance local healthcare delivery and bolster a hospital’s financial stability.

Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.

This week's research roundup feature: Implant-associated infections (IAIs) pose serious threats to patients and can be associated with significant morbidity and mortality. These infections may be difficult to diagnose due, in part, to biofilm formation on device surfaces, and because even when microbes are found, their clinical significance may be unclear. Despite recent advances in laboratory testing, IAIs remain a diagnostic challenge.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with Dan Nelson, a Mayo Clinic contract employee and laboratory connectivity expert. They discuss the unique needs and challenges that outreach labs face with information technology (IT) systems.

Join Mayo Clinic Laboratories at the American Academy of Neurology Annual Meeting 2024.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss important industry updates and legislative insights gathered from Dr. Morice’s recent trip to Washington, D.C.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he describes the untapped potential of hospital laboratories and how health systems can maximize the value of their labs.

Carrie began her career at Mayo Clinic in 2006 as the associate director of the Eisenberg Genomics Education Program. In her current role as a genetic counselor, she employs her skills to educate on genetic test offerings and support MCL’s product management team. Motivated by her family’s experience with a genetic condition, Carrie finds purpose and passion in sparking conversations and fostering understanding about the benefits of genetic testing, striving to make genomics accessible to diverse audiences.

Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for patients and their families.

This week's research roundup feature: The revised 4th edition of the World Health Organization (WHO4R) classification lists myelodysplastic syndromes with ring sideroblasts (MDS-RS) as a separate entity with single lineage (MDS-RS-SLD) or multilineage (MDS-RS-MLD) dysplasia. The more recent International Consensus Classification (ICC) distinguishes between MDS with SF3B1 mutation (MDS-SF3B1) and MDS-RS without SF3B1 mutation; the latter is instead included under the category of MDS not otherwise specified. The current study includes 170 Mayo Clinic patients with WHO4R-defined MDS-RS, including MDS-RS-SLD (N=83) and MDS-RS-MLD (N=87); a subset of 145 patients were also evaluable for the presence of SF3B1 and other mutations, including 126 with (87%) and 19 (13%) without SF3B1 mutation.

With many organizations using a digital-first approach, it is easy to assume that is always the best option. But is it? And what about for your laboratory outreach program? Laboratories should consider these seven S’s when deciding whether connectivity will align with the goals of their outreach programs.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Reade Quinton, M.D., assistant professor of laboratory medicine and pathology, to discuss[...]